A multicenter, single-arm phase II study on the efficacy and safety of Toripalimab combined with chemoradiotherapy for recurrent or metastatic cervical cancer
Latest Information Update: 05 Feb 2020
Price :
$35 *
At a glance
- Drugs Toripalimab (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 05 Feb 2020 New trial record